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Introduction {#jdi13157-sec-0001}
============

Familial renal glucosuria (FRG) is a rare renal tubular disorder characterized by isolated persistent glucosuria without hyperglycemia[1](#jdi13157-bib-0001){ref-type="ref"}. Mutations in the solute carrier family 5 member 2 (*SLC5A2*) gene, which encodes sodium--glucose cotransporter 2 (SGLT2), are responsible for the vast majority of FRG cases[2](#jdi13157-bib-0002){ref-type="ref"}, [3](#jdi13157-bib-0003){ref-type="ref"}. Most individuals with heterozygous mutations have mild glucosuria; those with homozygous or compound heterozygous mutations usually have severe glucosuria. In pedigrees with mild glucosuria, FRG is often inherited as an autosomal dominant trait[4](#jdi13157-bib-0004){ref-type="ref"}; pedigrees with severe glucosuria suggest autosomal recessive inheritance[5](#jdi13157-bib-0005){ref-type="ref"}. However, recent studies have shown that inheritance of FRG might best be described as a codominant trait with variable penetrance[2](#jdi13157-bib-0002){ref-type="ref"}.

SGLT2 inhibitors have been proposed as a novel approach for the treatment of diabetes; such inhibitors are a new category of glucose‐lowering drugs with insulin‐independent action. Thus, FRG patients might provide an ideal model for evaluating the long‐term safety of these agents.

FRG has been suggested to have a prevalence of 0.007% in Japanese schoolchildren[6](#jdi13157-bib-0006){ref-type="ref"}. However, the genetic basis of FRG in Japan is largely unknown. In the present study, clinical and genetic findings are described in a family with FRG associated with a *SLC5A2* gene mutation.

Methods {#jdi13157-sec-0002}
=======

Participants {#jdi13157-sec-0003}
------------

The pedigree of a family with FRG is shown in Figure [1](#jdi13157-fig-0001){ref-type="fig"}. The proband was a 26‐year‐old Japanese man who was referred to the diabetes division because of repeated glucosuria. The patient was first noted to have glucosuria without hyperglycemia and any other symptoms at the age of 3 years. His growth rate and intellectual development were normal.

![Pedigree of a family with familial renal glucosuria. The proband (P) is indicated by the arrow. His mother, uncle and grandfather (deceased \[d.\]) also have or had a history of glucosuria. His mother was first noted to have glucosuria without hyperglycemia at the age of 11 years. His uncle was first noted to have glucosuria without hyperglycemia at the age of 22 years. His grandfather was first noted to have glucosuria at the age of 27 years, when he was prescribed a medicine, the details of which are unknown. After taking the prescribed medicine, he became comatose and was transported to an emergency room. At that time, he was diagnosed with renal glucosuria. N101K, asparagine‐to‐lysine substitution at position 101 of the sodium--glucose cotransporter 2 protein; WT, wild type.](JDI-11-573-g001){#jdi13157-fig-0001}

Genetic analysis {#jdi13157-sec-0004}
----------------

After obtaining informed consent from the patient and his parents, blood samples were collected. Genomic DNA was extracted from peripheral white blood cells using the Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA). We sequenced 14 coding exons in *SLC5A2* together with their flanking intronic regions (Appendix [S1](#jdi13157-sup-0004){ref-type="supplementary-material"}; Table [S1](#jdi13157-sup-0003){ref-type="supplementary-material"}).

Pathogenicity prediction {#jdi13157-sec-0005}
------------------------

The functional consequences of mutations were predicted using three online tools: Polyphen 2 (<http://genetics.bwh.harvard.edu/pph2/>), SIFT (<http://sift.jcvi.org>) and MutationTaster (<http://www.mutationtaster.org>). These *in silico* tools predict the effect of an amino acid substitution on protein function based on the degree of the conservation of the amino acid residues and the changes of protein structure[7](#jdi13157-bib-0007){ref-type="ref"}, [8](#jdi13157-bib-0008){ref-type="ref"}, [9](#jdi13157-bib-0009){ref-type="ref"}.

Continuous glucose monitoring {#jdi13157-sec-0006}
-----------------------------

To evaluate the possible pathogenic effect of the *SLC5A2* mutation on glycemic excursion, daily glucose profiles and low‐glucose events were monitored for 14 consecutive days with a continuous glucose monitoring (CGM) system (FreeStyle Libre; Abbott Japan Co., Ltd., Chiba, Japan).

Ethical considerations {#jdi13157-sec-0007}
----------------------

Ethical approval for this study was obtained from the ethics committee of Koseiren Tsurumi Hospital (approval No. 19‐006), and the study conforms to the provisions of the Declaration of Helsinki.

Results {#jdi13157-sec-0008}
=======

Clinical characteristics of the participants are shown in Table [1](#jdi13157-tbl-0001){ref-type="table"}. Laboratory tests, such as blood glucose and fasting counter‐regulatory hormones, detected no abnormalities, except for glucosuria. The proband's glucose tolerance was normal during a 3‐h, 75‐g oral glucose tolerance test.

###### 

Laboratory findings and medication of the proband and parents

                                                  Proband   Father   Mother                                      Proband   Father   Mother
  ----------------------------------------------- --------- -------- -------- ---------------------------------- --------- -------- --------
  Age (years)                                     26        52       50       Glucose metabolism                                     
  Height (cm)                                     174.0     179.3    157.9    Fasting plasma glucose (mg/dL)     91        99       89
  Weight (kg)                                     72.0      83.2     52.9     IRI (μU/mL)                        5.9                3.7
  BMI (kg/m^2^)                                   23.8      25.9     21.2     C‐peptide (ng/mL)                  1.75               0.99
  Blood pressure (mmHg)                           130/77    143/95   121/70   Hemoglobin A1c (%)                 5.3       5.7      5.4
  HOMA‐R                                          1.33               0.81                                                           
  Urine testing                                                               Insulinogenic index                1.78                
  pH                                              6.0       5.0      5.0                                                             
  Protein                                         --        --       --       75‐g Oral glucose tolerance test                       
  Glucose                                         4+        --       --       Plasma glucose (mg/dL)                                 
  Ketone                                          --                 --       0 min                              91                  
  Blood                                           --        --       --       30 min                             119                 
  Urine glucose (g/1.73 m^2^/24 h)                43.0               0.2      60 min                             106                 
                                                                              90 min                             100                 
  Biochemistry                                                                120 min                            103                 
  Total cholesterol (mg/dL)                       203       241      240      180 min                            83                  
  Triglyceride (mg/dL)                            80        145      41                                                              
  High‐density lipoprotein (mg/dL)                64        53       94       Serum IRI (μU/mL)                                      
  Blood urea nitrogen (mg/dL)                     24.1      15.5     9.0      0 min                              5.9                 
  Creatinine (mg/dL)                              0.70      0.95     0.72     30 min                             55.6                
  eGFR (mL/min/1.73 m^2^)                         115.1     66.0     66.8     60 min                             24.8                
  Sodium (mEq/L)                                  139                142      90 min                             44.7                
  Potassium (mEq/L)                               3.9                3.7      120 min                            37.2                
  Chloride (mEq/L)                                102                106      180 min                            5.1                 
  Counter‐regulatory hormones                                                 Urine glucose (mg/dL)                                  
  Glucagon (5.4--55.0 pg/mL)                      19.6               18.0     0 min                              3,320               
  Adrenocorticotropic hormone (7.2--63.3 pg/mL)   23.9               27.6     30 min                             4,502               
  Cortisol (6.24--18.0 μg/dL)                     6.77               8.71     60 min                             6,036               
  Growth horme (Male; ≤2.47 ng/mL)                0.40                        90 min                             5,132               
  Growth hormone (Female; 0.13--9.88 ng/mL)                           1.46    120 min                            5,373               
  Adrenaline (≤100 pg/mL)                         15                 38       180 min                            4,650               
  Noradrenaline (100--450 pg/mL)                  139                133                                                             
  Dopamine (≤20 pg/mL)                            ≤5                 ≤5       Medication                         (−)       (--)     (−)

Fasting plasma glucagon levels were measured using the sandwich enzyme‐linked immuno sorbent assay (Mercodia, Uppsala, Sweden). BMI, body mass index; eGFR, estimated glomerular filtration rate; HOMA‐R, homeostasis model assessment for insulin resistance; IRI, immunoreactive insulin.
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A T‐to‐A transition at complementary deoxyribonucleic acid (cDNA) position 303 of *SLC5A2* (c.303T\>A) was identified in the patient and his mother; this mutation corresponded to an asparagine‐to‐lysine substitution at position 101 of the SGLT2 protein (N101K) (Figure [2](#jdi13157-fig-0002){ref-type="fig"}). The proband and his mother were heterozygous for the mutation. The mutation was not detected in the proband's father, nor in 200 chromosomes derived from 100 healthy, unrelated individuals.

![Genomic deoxyribonucleic acid sequence analysis of the solute carrier family 5 member 2 gene in members of a family with familial renal glucosuria. A T‐to‐A transition at solute carrier family 5 member 2 complementary deoxyribonucleic acid position 303 (indicated by the red arrows) results in an asparagine‐to‐lysine substitution at amino acid residue 101 of the sodium--glucose cotransporter 2 protein (N101K). The proband and his mother were heterozygous for the mutation (c.303T \> A). His father did not harbor this mutation, nor was the mutation detected in 200 chromosomes derived from 100 healthy, unrelated individuals. The left column shows the forward sequences, and the right column shows the reverse sequences.](JDI-11-573-g002){#jdi13157-fig-0002}

Online analysis using Polyphen 2, SIFT and MutationTaster suggested that the N101K mutation would be deleterious and could be associated with FRG (Figure [S1](#jdi13157-sup-0001){ref-type="supplementary-material"}).

Although the proband did not complain of symptoms of hypoglycemia, two weeks of CGM showed both nocturnal and diurnal asymptomatic hypoglycemia (\<70 mg/dL) for a mean of 236 min/day (Figure [3](#jdi13157-fig-0003){ref-type="fig"}).

![(a) Daily glucose profiles and (b) low‐glucose events for 14 consecutive days during monitoring with a continuous glucose monitoring system (the FreeStyle Libre). The red lines indicate hypoglycemia (\<70 mg/dL), and the blue lines indicate the appropriate blood glucose level (70--140 mg/dL). Open circles indicate when the proband checked blood glucose levels. The closed circle indicates the start of continuous glucose monitoring.](JDI-11-573-g003){#jdi13157-fig-0003}

Discussion {#jdi13157-sec-0009}
==========

In healthy individuals, the kidneys filter approximately 180 g of glucose per day; nearly 100% of the glucose is reabsorbed in the proximal convoluted tubule through SGLTs to maintain glucose homeostasis[10](#jdi13157-bib-0010){ref-type="ref"}. SGLT2 is responsible for the active transport of glucose across the brush border membrane, and is expressed almost exclusively in the kidney, accounting for the bulk of glucose reabsorption[10](#jdi13157-bib-0010){ref-type="ref"}. Mutations in the *SLC5A2* gene, which encodes SGLT2, have been reported to be responsible for FRG[2](#jdi13157-bib-0002){ref-type="ref"}, [3](#jdi13157-bib-0003){ref-type="ref"}.

In the present study, a heterozygous missense mutation (c.303T\>A:p.N101K) in *SLC5A2* was identified in a Japanese family with FRG. This mutation was not detected in 200 chromosomes from 100 healthy and unrelated individuals, or in 3,408 Japanese individuals in the Tohoku Medical Megabank, which is the largest genome database based on whole‐genome sequences of the Japanese general population (<https://jmorp.megabank.tohoku.ac.jp/201905/variants/by-gene/SLC5A2>). In the Genome Aggregation Database derived from 123,136 exome sequences and 15,496 whole‐genome sequences from unrelated individuals sequenced as part of various disease‐specific and population genetic studies, only one example of this variant (rs1306939757) has been reported, corresponding to a frequency of 0.0000319 (<http://gnomad.broadinstitute.org/>), indicating the rarity of this variant. The N101 amino acid residue was found to be highly conserved across SGLT2 homologs in multiple species and among human SGLT subtypes (Figure [S2](#jdi13157-sup-0002){ref-type="supplementary-material"}). In humans, only SGLT3, which is encoded by the *SLC5A4* gene, harbors a replacement of the asparagine residue (by threonine). However, SGLT3 is not a cotransporter, but rather a glucosensor expressed in cholinergic neurons at the neuromuscular junction[11](#jdi13157-bib-0011){ref-type="ref"}, suggesting that the N101 amino acid residue in those SLC5 members that co‐transport glucose might play a critical role in the symporter function. Furthermore, all three of the bioinformatics programs consulted here predicted that the N101K mutation would be pathogenic (Figure [S1](#jdi13157-sup-0001){ref-type="supplementary-material"}). Further work will be required to prove that the N101K mutation actually results in a loss of function, thereby increasing renal glucosuria. Given the clinical manifestations shown by the patient, we infer that the mutation leads to clinically relevant SGLT2 dysfunction. Notably, in the present study, the heterozygous patient had severe glucosuria (urine glucose: 43.0 g/1.73 m^2^/24 h), whereas his mother (also heterozygous for the same mutation) did not (urine glucose: 0.2 g/1.73 m^2^/24 h). This result indicates that the inheritance of renal glucosuria is best described as codominant, and its variable penetrance might relate to the compensatory ability of the wild‐type allele or environment factors might be associated with the glucose reabsorption[2](#jdi13157-bib-0002){ref-type="ref"}. Notably, although *Sglt2*−/− mice excrete much of the filtered glucose, urinary glucose concentrations do not appreciably differ between *Sglt2*+/− and wild‐type mice, indicating that one intact *Sglt2* allele is sufficient to achieve normal renal glucose reabsorption[12](#jdi13157-bib-0012){ref-type="ref"}.

To our knowledge, this pedigree represents the first case in which CGM has been carried out in a patient with FRG. Renal glucosuria is thought to be a "non‐disease"; the great majority of affected individuals do not have any complaints, and only rarely have been reported to show a propensity to hypoglycemia[2](#jdi13157-bib-0002){ref-type="ref"}, [13](#jdi13157-bib-0013){ref-type="ref"}. However, CGM of this proband suggested the presence of asymptomatic hypoglycemia (as judged by frequency and severity; Figure [3](#jdi13157-fig-0003){ref-type="fig"}) in an otherwise asymptomatic FRG patient. Because of their experience with extended hypoglycemic periods since birth, patients with FRG might be accustomed to hypoglycemia.

The present study had two limitations. First, hypoglycemia was detected with CGM, but not by laboratory test or by self‐monitoring of blood glucose. Conflicting data about the accuracy of CGM at low‐glucose levels have been reported[14](#jdi13157-bib-0014){ref-type="ref"}, [15](#jdi13157-bib-0015){ref-type="ref"}. Second, details of clinical phenotypes were studied only in a proband in the present study. Urinary glucose excretion in FRG varies widely among patients, ranging from 0.6 to 202 g/1.73 m^2^/24 h[2](#jdi13157-bib-0002){ref-type="ref"}, [16](#jdi13157-bib-0016){ref-type="ref"}. The present patient excreted large amounts of urinary glucose, despite being heterozygous for the mutation. Although FRG has been considered to be a "non‐disease," the condition sometimes might be accompanied by asymptomatic hypoglycemia on an everyday basis, as shown in the present case. Further studies on CGM in patients with FRG will be required to define the pathological characteristics of this disease.

Disclosure {#jdi13157-sec-0010}
==========
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